BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35064107)

  • 1. N6-methyladenosine demethylase FTO promotes growth and metastasis of gastric cancer via m
    Zhou Y; Wang Q; Deng H; Xu B; Zhou Y; Liu J; Liu Y; Shi Y; Zheng X; Jiang J
    Cell Death Dis; 2022 Jan; 13(1):72. PubMed ID: 35064107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTO demethylates m6A modifications in CDKAL1 mRNA and promotes gastric cancer chemoresistance by altering mitochondrial dynamics.
    Liu N; Liu C; Wang Z; Wang L; Wang J; Kong J
    Clin Exp Pharmacol Physiol; 2023 Apr; 50(4):307-315. PubMed ID: 36628934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
    Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
    Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner.
    Huang J; Sun W; Wang Z; Lv C; Zhang T; Zhang D; Dong W; Shao L; He L; Ji X; Zhang P; Zhang H
    J Exp Clin Cancer Res; 2022 Jan; 41(1):42. PubMed ID: 35090515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Demethylase Genes, FTO and ALKBH1, Is Associated with Prognosis of Gastric Cancer.
    Li Y; Zheng D; Wang F; Xu Y; Yu H; Zhang H
    Dig Dis Sci; 2019 Jun; 64(6):1503-1513. PubMed ID: 30637548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis.
    Lin Z; Wan AH; Sun L; Liang H; Niu Y; Deng Y; Yan S; Wang QP; Bu X; Zhang X; Hu K; Wan G; He W
    Mol Ther; 2023 Feb; 31(2):517-534. PubMed ID: 36307991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N6-methyladenosine demethylase FTO impairs hepatic ischemia-reperfusion injury via inhibiting Drp1-mediated mitochondrial fragmentation.
    Du YD; Guo WY; Han CH; Wang Y; Chen XS; Li DW; Liu JL; Zhang M; Zhu N; Wang X
    Cell Death Dis; 2021 May; 12(5):442. PubMed ID: 33947842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTO facilitates cancer metastasis by modifying the m
    Gao L; Wang A; Chen Y; Cai X; Li Y; Zhao J; Zhang Y; Zhang W; Zhu J; Zeng Y; Liu Z; Huang JA
    Cell Commun Signal; 2023 Nov; 21(1):311. PubMed ID: 37919739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA N6-methyladenosine demethylase FTO promotes osteoporosis through demethylating Runx2 mRNA and inhibiting osteogenic differentiation.
    Wang J; Fu Q; Yang J; Liu JL; Hou SM; Huang X; Cao JS; Liu TL; Wang KZ
    Aging (Albany NY); 2021 Sep; 13(17):21134-21141. PubMed ID: 34496349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTO promotes gastric cancer progression by modulating MAP4K4 expression via demethylation in an m6A-dependent manner.
    Yin Z; Guo X; Liang X; Wang Z
    Med Oncol; 2024 Apr; 41(5):120. PubMed ID: 38643333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression.
    Song W; Yang K; Luo J; Gao Z; Gao Y
    Aging (Albany NY); 2021 Jan; 13(3):3909-3925. PubMed ID: 33461172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA N6-methyladenosine demethylase FTO targets MOXD1 promoting the malignant phenotype of gastric cancer.
    Lai Y; Dong H; Xu P; Wang J; Feng W; Zhao Z; Sha L
    BMC Gastroenterol; 2024 Jan; 24(1):29. PubMed ID: 38200441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells.
    Tsuruta N; Tsuchihashi K; Ohmura H; Yamaguchi K; Ito M; Ariyama H; Kusaba H; Akashi K; Baba E
    Biochem Biophys Res Commun; 2020 Sep; 530(1):235-239. PubMed ID: 32828292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FTO mediated ERBB2 demethylation promotes tumor progression in esophageal squamous cell carcinoma cells.
    Zhao F; Ge F; Xie M; Li Z; Zang C; Kong L; Pu Y; Zheng X; Tan Y
    Clin Exp Metastasis; 2022 Aug; 39(4):623-639. PubMed ID: 35524932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NADP modulates RNA m
    Wang L; Song C; Wang N; Li S; Liu Q; Sun Z; Wang K; Yu SC; Yang Q
    Nat Chem Biol; 2020 Dec; 16(12):1394-1402. PubMed ID: 32719557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel positioning from obesity to cancer: FTO, an m
    Chen J; Du B
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):19-29. PubMed ID: 30465076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tumor-suppressive effects of alpha-ketoglutarate-dependent dioxygenase FTO via N6-methyladenosine RNA methylation on bladder cancer patients.
    Yi W; Yu Y; Li Y; Yang J; Gao S; Xu L
    Bioengineered; 2021 Dec; 12(1):5323-5333. PubMed ID: 34499008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fat mass and obesity associated (FTO)-mediated N6-methyladenosine modification of Krüppel-like factor 3 (KLF3) promotes osteosarcoma progression.
    Shan HJ; Gu WX; Duan G; Chen HL
    Bioengineered; 2022 Apr; 13(4):8038-8050. PubMed ID: 35311620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel evidence for m
    Shimura T; Kandimalla R; Okugawa Y; Ohi M; Toiyama Y; He C; Goel A
    Br J Cancer; 2022 Feb; 126(2):228-237. PubMed ID: 34675398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SIRT1 Regulates N
    Liu X; Liu J; Xiao W; Zeng Q; Bo H; Zhu Y; Gong L; He D; Xing X; Li R; Zhou M; Xiong W; Zhou Y; Zhou J; Li X; Guo F; Xu C; Chen X; Wang X; Wang F; Wang Q; Cao K
    Hepatology; 2020 Dec; 72(6):2029-2050. PubMed ID: 32154934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.